Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease
Identifieur interne : 002320 ( Istex/Corpus ); précédent : 002319; suivant : 002321Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease
Auteurs : Andrew Lees ; Stanley Fahn ; Karla M. Eggert ; Joseph Jankovic ; Anthony Lang ; Federico Micheli ; M. Maral Mouradian ; Wolfgang H. Oertel ; C. Warren Olanow ; Werner Poewe ; Olivier Rascol ; Eduardo Tolosa ; David Squillacote ; Dinesh KumarSource :
- Movement Disorders [ 0885-3185 ] ; 2012-02.
English descriptors
- KwdEn :
Abstract
Perampanel is a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor antagonist. Two multicenter randomized, double‐blind, placebo‐controlled, parallel‐group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations.
Url:
DOI: 10.1002/mds.23983
Links to Exploration step
ISTEX:C8FC6F258A678C36B801D2375E63FFB5F31FC7F3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease</title><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Reta Lila Weston Institute for Neurological Studies, University College London, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation><mods:affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name><affiliation><mods:affiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><affiliation><mods:affiliation>Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina</mods:affiliation></affiliation></author><author><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name><affiliation><mods:affiliation>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School, Piscataway, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation><mods:affiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name><affiliation><mods:affiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name><affiliation><mods:affiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C8FC6F258A678C36B801D2375E63FFB5F31FC7F3</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/mds.23983</idno><idno type="url">https://api-v5.istex.fr/document/C8FC6F258A678C36B801D2375E63FFB5F31FC7F3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002320</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002320</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease</title><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Reta Lila Weston Institute for Neurological Studies, University College London, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation><mods:affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name><affiliation><mods:affiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><affiliation><mods:affiliation>Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina</mods:affiliation></affiliation></author><author><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name><affiliation><mods:affiliation>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School, Piscataway, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation><mods:affiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name><affiliation><mods:affiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</mods:affiliation></affiliation></author><author><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name><affiliation><mods:affiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-02">2012-02</date><biblScope unit="volume">27</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="284">284</biblScope><biblScope unit="page" to="288">288</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C8FC6F258A678C36B801D2375E63FFB5F31FC7F3</idno><idno type="DOI">10.1002/mds.23983</idno><idno type="ArticleID">MDS23983</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AMPA receptor antagonist</term><term>Parkinson's disease</term><term>efficacy</term><term>motor fluctuations</term><term>perampanel</term><term>safety</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Perampanel is a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor antagonist. Two multicenter randomized, double‐blind, placebo‐controlled, parallel‐group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Andrew Lees MD, FRCP</name><affiliations><json:string>Reta Lila Weston Institute for Neurological Studies, University College London, London, United Kingdom</json:string><json:string>Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, United Kingdom</json:string></affiliations></json:item><json:item><name>Stanley Fahn MD</name><affiliations><json:string>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Karla M. Eggert MD</name><affiliations><json:string>Department of Neurology, Philipps University Marburg, Marburg, Germany</json:string></affiliations></json:item><json:item><name>Joseph Jankovic MD</name><affiliations><json:string>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</json:string></affiliations></json:item><json:item><name>Anthony Lang MD</name><affiliations><json:string>Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Federico Micheli MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina</json:string></affiliations></json:item><json:item><name>M. Maral Mouradian MD</name><affiliations><json:string>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School, Piscataway, New Jersey, USA</json:string></affiliations></json:item><json:item><name>Wolfgang H. Oertel MD</name><affiliations><json:string>Department of Neurology, Philipps University Marburg, Marburg, Germany</json:string></affiliations></json:item><json:item><name>C. Warren Olanow MD, FRCPC</name><affiliations><json:string>Mount Sinai School of Medicine, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse, Toulouse, France</json:string></affiliations></json:item><json:item><name>Eduardo Tolosa MD</name><affiliations><json:string>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>David Squillacote MD</name><affiliations><json:string>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</json:string></affiliations></json:item><json:item><name>Dinesh Kumar MS</name><affiliations><json:string>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>AMPA receptor antagonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>efficacy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>motor fluctuations</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>perampanel</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>safety</value></json:item></subject><articleId><json:string>MDS23983</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>5.408</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>330</abstractCharCount><pdfWordCount>10601</pdfWordCount><pdfCharCount>70290</pdfCharCount><pdfPageCount>17</pdfPageCount><abstractWordCount>34</abstractWordCount></qualityIndicators><title>Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>27</volume><issue>2</issue><pages><first>284</first><last>288</last><total>5</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Brief Report</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1002/mds.23983</json:string></doi><id>C8FC6F258A678C36B801D2375E63FFB5F31FC7F3</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/C8FC6F258A678C36B801D2375E63FFB5F31FC7F3/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/C8FC6F258A678C36B801D2375E63FFB5F31FC7F3/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/C8FC6F258A678C36B801D2375E63FFB5F31FC7F3/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2011 Movement Disorder Society</p></availability><date>2012</date></publicationStmt><notesStmt><note type="content">*Funding agencies: These studies were funded by Eisai Inc.</note><note type="content">*Relevant conflicts of interest/financial disclosures: All authors received compensation from Eisai for their site's conduct of the study and/or as members of steering committees. Joseph Jankovic has received honoraria as a consultant to Eisai. Anthony Lang, M. Maral Mouradian, Olivier Rascol, and C. Warren Olanow have served as advisers or consultants for Eisai. David Squillacote and Dinesh Kumar are employed by Eisai.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease</title><author xml:id="author-1"><persName><forename type="first">Andrew</forename><surname>Lees</surname></persName><roleName type="degree">MD, FRCP</roleName><affiliation>Reta Lila Weston Institute for Neurological Studies, University College London, London, United Kingdom</affiliation><affiliation>Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, United Kingdom</affiliation></author><author xml:id="author-2"><persName><forename type="first">Stanley</forename><surname>Fahn</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</affiliation></author><author xml:id="author-3"><persName><forename type="first">Karla M.</forename><surname>Eggert</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</affiliation></author><author xml:id="author-4"><persName><forename type="first">Joseph</forename><surname>Jankovic</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</affiliation></author><author xml:id="author-5"><persName><forename type="first">Anthony</forename><surname>Lang</surname></persName><roleName type="degree">MD</roleName><affiliation>Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada</affiliation></author><author xml:id="author-6"><persName><forename type="first">Federico</forename><surname>Micheli</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina</affiliation></author><author xml:id="author-7"><persName><forename type="first">M.</forename><surname>Maral Mouradian</surname></persName><roleName type="degree">MD</roleName><affiliation>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School, Piscataway, New Jersey, USA</affiliation></author><author xml:id="author-8"><persName><forename type="first">Wolfgang H.</forename><surname>Oertel</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</affiliation></author><author xml:id="author-9"><persName><forename type="first">C. Warren</forename><surname>Olanow</surname></persName><roleName type="degree">MD, FRCPC</roleName><affiliation>Mount Sinai School of Medicine, New York, New York, USA</affiliation></author><author xml:id="author-10"><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation></author><author xml:id="author-11"><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse, Toulouse, France</affiliation></author><author xml:id="author-12"><persName><forename type="first">Eduardo</forename><surname>Tolosa</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain</affiliation></author><author xml:id="author-13"><persName><forename type="first">David</forename><surname>Squillacote</surname></persName><roleName type="degree">MD</roleName><affiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</affiliation></author><author xml:id="author-14"><persName><forename type="first">Dinesh</forename><surname>Kumar</surname></persName><roleName type="degree">MS</roleName><affiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-02"></date><biblScope unit="volume">27</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="284">284</biblScope><biblScope unit="page" to="288">288</biblScope></imprint></monogr><idno type="istex">C8FC6F258A678C36B801D2375E63FFB5F31FC7F3</idno><idno type="DOI">10.1002/mds.23983</idno><idno type="ArticleID">MDS23983</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2012</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Perampanel is a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor antagonist. Two multicenter randomized, double‐blind, placebo‐controlled, parallel‐group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations.</p></abstract><abstract><p>In both phase III studies (301 and 302), levodopa‐treated patients were randomized and treated with once‐daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily “off” time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302.</p></abstract><abstract><p>For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day.</p></abstract><abstract><p>Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa‐induced dyskinesia. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>AMPA receptor antagonist</term></item><item><term>efficacy</term></item><item><term>motor fluctuations</term></item><item><term>Parkinson's disease</term></item><item><term>perampanel</term></item><item><term>safety</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-06-02">Received</change><change when="2011-09-12">Registration</change><change when="2012-02">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/C8FC6F258A678C36B801D2375E63FFB5F31FC7F3/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v27.2</doi><numberingGroup><numbering type="journalVolume" number="27">27</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2012-02">February 2012</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="210" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23983</doi><idGroup><id type="unit" value="MDS23983"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-06-02"></event><event type="manuscriptRevised" date="2011-08-03"></event><event type="manuscriptAccepted" date="2011-09-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.2.1 standalone mode:FullText" date="2012-02-10"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-12-09"></event><event type="publishedOnlineFinalForm" date="2012-02-09"></event><event type="firstOnline" date="2011-12-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-24"></event></eventGroup><numberingGroup><numbering type="pageFirst">284</numbering><numbering type="pageLast">288</numbering></numberingGroup><correspondenceTo>Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23983.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="14"></count><count type="wordTotal" number="5691"></count></countGroup><titleGroup><title type="main" xml:lang="en">Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease<link href="#fn5"></link><link href="#fn6"></link><link href="#fn7"></link></title><title type="short" xml:lang="en">Perampanel in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Andrew</givenNames><familyName>Lees</familyName><degrees>MD, FRCP</degrees></personName><contactDetails><email>alees@ion.ucl.ac.uk</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Stanley</givenNames><familyName>Fahn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Karla M.</givenNames><familyName>Eggert</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Joseph</givenNames><familyName>Jankovic</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Anthony</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Federico</givenNames><familyName>Micheli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7"><personName><givenNames>M.</givenNames><familyName>Maral Mouradian</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Wolfgang H.</givenNames><familyName>Oertel</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af8"><personName><givenNames>C. Warren</givenNames><familyName>Olanow</familyName><degrees>MD, FRCPC</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Eduardo</givenNames><familyName>Tolosa</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af12"><personName><givenNames>David</givenNames><familyName>Squillacote</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Dinesh</givenNames><familyName>Kumar</familyName><degrees>MS</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Reta Lila Weston Institute for Neurological Studies, University College London, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="CA" type="organization"><unparsedAffiliation>Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="AR" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School, Piscataway, New Jersey, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="US" type="organization"><unparsedAffiliation>Mount Sinai School of Medicine, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="FR" type="organization"><unparsedAffiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="ES" type="organization"><unparsedAffiliation>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="US" type="organization"><unparsedAffiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">AMPA receptor antagonist</keyword><keyword xml:id="kwd2">efficacy</keyword><keyword xml:id="kwd3">motor fluctuations</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword><keyword xml:id="kwd5">perampanel</keyword><keyword xml:id="kwd6">safety</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background:</title><p>Perampanel is a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor antagonist. Two multicenter randomized, double‐blind, placebo‐controlled, parallel‐group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>In both phase III studies (301 and 302), levodopa‐treated patients were randomized and treated with once‐daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily “off” time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302.</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day.</p></section><section xml:id="abs1-4"><title type="main">Conclusions:</title><p>Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa‐induced dyskinesia. © 2011 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn5"><p><b>Funding agencies:</b> These studies were funded by Eisai Inc.</p></note><note xml:id="fn6"><p><b>Relevant conflicts of interest/financial disclosures:</b> All authors received compensation from Eisai for their site's conduct of the study and/or as members of steering committees. Joseph Jankovic has received honoraria as a consultant to Eisai. Anthony Lang, M. Maral Mouradian, Olivier Rascol, and C. Warren Olanow have served as advisers or consultants for Eisai. David Squillacote and Dinesh Kumar are employed by Eisai.</p></note><note xml:id="fn7"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Perampanel in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">MD, FRCP</namePart><affiliation>Reta Lila Weston Institute for Neurological Studies, University College London, London, United Kingdom</affiliation><affiliation>Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stanley</namePart><namePart type="family">Fahn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karla M.</namePart><namePart type="family">Eggert</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Jankovic</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Federico</namePart><namePart type="family">Micheli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Maral Mouradian</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School, Piscataway, New Jersey, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wolfgang H.</namePart><namePart type="family">Oertel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Philipps University Marburg, Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. Warren</namePart><namePart type="family">Olanow</namePart><namePart type="termsOfAddress">MD, FRCPC</namePart><affiliation>Mount Sinai School of Medicine, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduardo</namePart><namePart type="family">Tolosa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Squillacote</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dinesh</namePart><namePart type="family">Kumar</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Eisai Neuroscience Product Creation Unit, Woodcliff Lake, New Jersey, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2012-02</dateIssued><dateCaptured encoding="w3cdtf">2011-06-02</dateCaptured><dateValid encoding="w3cdtf">2011-09-12</dateValid><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">14</extent><extent unit="words">5691</extent></physicalDescription><abstract>Perampanel is a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor antagonist. Two multicenter randomized, double‐blind, placebo‐controlled, parallel‐group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations.</abstract><abstract>In both phase III studies (301 and 302), levodopa‐treated patients were randomized and treated with once‐daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily “off” time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302.</abstract><abstract>For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day.</abstract><abstract>Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa‐induced dyskinesia. © 2011 Movement Disorder Society</abstract><note type="content">*Funding agencies: These studies were funded by Eisai Inc.</note><note type="content">*Relevant conflicts of interest/financial disclosures: All authors received compensation from Eisai for their site's conduct of the study and/or as members of steering committees. Joseph Jankovic has received honoraria as a consultant to Eisai. Anthony Lang, M. Maral Mouradian, Olivier Rascol, and C. Warren Olanow have served as advisers or consultants for Eisai. David Squillacote and Dinesh Kumar are employed by Eisai.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>keywords</genre><topic>AMPA receptor antagonist</topic><topic>efficacy</topic><topic>motor fluctuations</topic><topic>Parkinson's disease</topic><topic>perampanel</topic><topic>safety</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>284</start><end>288</end><total>5</total></extent></part></relatedItem><identifier type="istex">C8FC6F258A678C36B801D2375E63FFB5F31FC7F3</identifier><identifier type="DOI">10.1002/mds.23983</identifier><identifier type="ArticleID">MDS23983</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002320 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002320 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:C8FC6F258A678C36B801D2375E63FFB5F31FC7F3
|texte= Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |